110 related articles for article (PubMed ID: 17088991)
21. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
22. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
23. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
24. In vivo dosimetry in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer--a phantom study.
Anton M; Wagner D; Selbach HJ; Hackel T; Hermann RM; Hess CF; Vorwerk H
Phys Med Biol; 2009 May; 54(9):2915-31. PubMed ID: 19384000
[TBL] [Abstract][Full Text] [Related]
25. [Combined treatment of localized prostate cancer with HDR-Iridium 192 remote brachytherapy and external beam irradiation].
Andreopoulos D; Piatkowiak M; Krenkel B; Schleicher UM; Wolff JM
Strahlenther Onkol; 1999 Aug; 175(8):387-91. PubMed ID: 10481770
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
27. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
Kovács G; Pötter R; Loch T; Hammer J; Kolkman-Deurloo IK; de la Rosette JJ; Bertermann H
Radiother Oncol; 2005 Feb; 74(2):137-48. PubMed ID: 15734201
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
Adams Q; Hopfensperger KM; Kim Y; Wu X; Xu W; Shukla H; McGee J; Caster JM; Flynn RT
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1543-1550. PubMed ID: 30092333
[TBL] [Abstract][Full Text] [Related]
29. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
Lilleby W; Tafjord G; Raabe NK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
[TBL] [Abstract][Full Text] [Related]
30. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
31. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
32. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
33. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
34. MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer.
Kazi A; Godwin G; Simpson J; Sasso G
BMC Cancer; 2010 Sep; 10():472. PubMed ID: 20809986
[TBL] [Abstract][Full Text] [Related]
35. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.
Syed AM; Puthawala A; Sharma A; Gamie S; Londrc A; Cherlow JM; Damore SJ; Nazmy N; Sheikh KM; Ko SJ
Cancer Control; 2001; 8(6):511-21. PubMed ID: 11807421
[TBL] [Abstract][Full Text] [Related]
36. Four year clinical statistics of iridium-192 high dose rate brachytherapy.
Shigehara K; Mizokami A; Komatsu K; Koshida K; Namiki M
Int J Urol; 2006 Feb; 13(2):116-21. PubMed ID: 16563134
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
[TBL] [Abstract][Full Text] [Related]
38. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.
Cunha JA; Pouliot J; Weinberg V; Wang-Chesebro A; Roach M; Hsu IC
Brachytherapy; 2012; 11(5):348-53. PubMed ID: 21937284
[TBL] [Abstract][Full Text] [Related]
39. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
40. A method to estimate composite doses for organs at risk in prostate cancer patients treated with EBRT in combination with HDR BT.
Pettersson N; Johansson KA; Alsadius D; Tucker SL; Steineck G; Olsson C
Acta Oncol; 2014 Jun; 53(6):815-21. PubMed ID: 24460070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
